Neurogene Inc (NGNE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $32.48 (+0.22%), Market cap $0.44B, 52-week low–high $14.95 ~ $34.37.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Neurogene Inc are updated in real time on BlackAll Trade.
Neurogene Inc trades at $32.48 (+0.22%). Real-time quotes and charts are available on BlackAll Trade.
Neurogene Inc has a market cap of about $0.44B.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associa